The Pharma Data

DECEMBER 7, 2020

based clinical trials investigating interventions for high blood pressure between 2009-2018, just 52 were exclusively in Black people. While the numbers grew over that decade – from 3.9% (3 of 77 trials) in 2009 to 6.2% (9 of 146) in 2018 – the increase was not enough to be statistically significant.

Treatment 52

Treatment Clinical Trials Trials Doctors 52

The Pharma Data

NOVEMBER 11, 2020

McChesney is the founder and chief executive officer of Cloaked Therapeutics and Arbor Therapeutics, through which he has drawn on more than five decades of research in natural products chemistry to identify and develop novel cancer treatments. In 2009, he established Ironstone Separations Inc.,

Organic Chemistry 52

Organic Chemistry Science Pharmacy Pharmaceuticals 52

Conversations in Drug Development Trends

FEBRUARY 22, 2023

Rare Disease Day on February 28th is a chance for rare disease communities to come together as one and join in conversation with stakeholders searching for treatments, raising money to support research, and changing the way healthcare and governments interact with patients. What will have the greatest impact on rare disease patients in 2023?

Disease 52

Disease Clinical Trials Trials Treatment 52

Drug Target Review

JUNE 29, 2023

Success in the haematology space has really been driving this from the beginning, which is not surprising as haem doctors understand stem cell transplants; they’re used to working with a lot of the sort of toxicities that can come with cell therapies. When it comes down to cell biology itself, cells can do so many different things.

Therapies 113

Therapies Science Production Cell Biology 113

Drug & Device Law

JULY 24, 2023

The drug is still on the market, and it has other risks that the FDA has found significantly more serious – requiring a boxed warning – than a three-one hundredths-of one-percent (0.0003) increase in absolute incidence of bladder cancer. at *6 (plaintiff “has documents and formularies reaching back to only 2009”).

Testimonials 52

Testimonials Pharmacy FDA Doctors 52

Drug & Device Law

FEBRUARY 16, 2023

Plaintiffs claimed that “surgical treatments that do not use [bone] screws should be considered alternative designs,” and lost. The problem with this argument is that it really takes issue with the choice of treatment made by [plaintiff’s] physician, not with a specific fault of the [bone] screws sold by [the defendant]. 3d 760 (Tex.

FDA 59

FDA Production FDA Approval Treatment 59

Drug & Device Law

JUNE 6, 2022

Thus a confident learned intermediary’s testimony will defeat causation as a matter of law by stating that, notwithstanding a poor result, the treatment provided was standard of care, and even in hindsight they would not do anything different. 2009), reversed a plaintiff’s verdict for entry of judgment n.o.v. Schering Corp. ,

Testimonials 59

Testimonials Production Pharmaceuticals Treatment 59